drugset / Trial / NCT05603052

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

NCT05603052

Phase 3 Completed 2852 enrolled EuBiologics Co.,Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged 18 years and older

Timeline

Start
2022-07-11
Primary completion
2024-01-15
Completion
2024-01-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD1222 Vaccine
Subject EuCorVac-19 Vaccine

Indications